Results 101 to 110 of about 9,558 (217)

Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors [PDF]

, 2018
Indolylarylsulfones are a potent class of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors. In this review, the structure activity relationship (SAR) studies to improve the profile of sulfone L-737,126 discovered by ...
Famiglini, V., Silvestri, R.
core   +1 more source

Rilpivirine [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients

Journal of the International Association of Providers of AIDS Care, 2019
Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor–based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus ...
Niccolò Riccardi MD, Filippo Del Puente MD, Lucia Taramasso MD, Antonio Di Biagio MD   +3 more
doaj   +1 more source

Monitoring of Foreign Drug Safety Information

Безопасность и риск фармакотерапии, 2019
Analysis of administrative decisions of foreign regulatory authorities on the recoil of medicines and/or the need for changes in the instructions for their medical use due to changes in the safety profile, conducted by experts of the Scientific Centre ...
Editorial article
doaj   +1 more source

Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy. [PDF]

, 2019
Objective: To describe data with selected malignancies in people living with HIV (PLWH) and HIV in individuals affected by both conditions and to summarize drug-drug interactions (DDIs) with clinical recommendations for point-of-care review of ...
Chan, Alexandre, Klibanov, Olga, Olin, Jacqueline L, Spooner, Linda M   +3 more
core   +1 more source

Enteral Administration of Twice-Daily Dolutegravir and Rilpivirine as a Part of a Triple-Therapy Regimen in a Critically Ill Patient with HIV

Journal of the International Association of Providers of AIDS Care, 2017
The administration of antiretroviral therapy (ART) in intubated critically ill patients may be challenging. Limited pharmacokinetic data exist characterizing the effects of crushed ART with subsequent enteral administration on antiretroviral drug ...
Sarah Lynn Turley PharmD, BCPS, Patricia Pecora Fulco PharmD, BCPS, FASHP, AAHIVP   +1 more
doaj   +1 more source

Dolutegravir/rilpivirine for the treatment of HIV-1 infection

HIV/AIDS: Research and Palliative Care, 2018
Ellen Dowers,1 Francis Zamora,1 Lydia Aoun Barakat,2 Onyema Ogbuagu2 1Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, CT, USA; 2Yale AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA
Dowers E, Zamora F, Barakat LA, Ogbuagu O   +3 more
doaj  

Increasing CD4/CD8 ratio confirmed after two years of long-acting cabotegravir and rilpivirine in the SCohoLART study

Frontiers in Virology
BackgroundLong-acting (LA) cabotegravir plus rilpivirine (CAB/RPV) is an established maintenance option for virologically suppressed people with HIV (PWH), but long-term real-world data on immune balance and cardio-metabolic and renal markers remain ...
Gabriele Loi, Nicolò Capra, Riccardo Lolatto, Marcella Negri, Gaia Catalano, Flavia Passini, Nicolò Moschetta, Claudia Benelli, Silvia Nozza, Silvia Nozza, Antonella Castagna, Antonella Castagna, Camilla Muccini   +12 more
doaj   +1 more source

Implementation of long‐acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations

Journal of the International AIDS Society
Introduction Cabotegravir plus rilpivirine (CAB + RPV) is the first complete long‐acting (LA) regimen recommended for maintaining HIV‐1 virological suppression.
Cassidy A. Gutner, Laurent Hocqueloux, Celia Jonsson‐Oldenbüttel, Linos Vandekerckhove, Berend J. vanWelzen, Laurence Slama, María Crusells‐Canales, Julián Olalla Sierra, Rebecca DeMoor, Jenny Scherzer, Mounir Ait‐Khaled, Gilda Bontempo, Martin Gill, Natasha Patel, Ronald D'Amico, Kai Hove, Bryan Baugh, Nicola Barnes, Monica Hadi, Emma L. Low, Savita Bakhshi Anand, Alison Hamilton, Harmony P. Garges, Maggie Czarnogorski   +23 more
doaj   +1 more source

Highlights from the 9th IAS conference on HIV science, 23-26 July 2017, Paris, France [PDF]

, 2017
The 9th International AIDS Society Conference on HIV Science (IAS 2017) took place at the Palais des Congrès, in Paris, France, from 23 to 26 July 2017, chaired by Linda-Gail Bekker and Jean-François Delfraissy. It was organised by the International AIDS
Barber, Tristan J, Kinloch-de Loës, Sabine, Psomas, Christina K, Rutsaert, Sofie   +3 more
core   +2 more sources